PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Nguyen, Quan Dong
TI  - Intravitreal Aflibercept Has Long-Term Benefits in Treatment of DME
DP  - 2014  01
TA  - MD Conference Express
PG  - 10--10
VI  - 14
IP  - 43
4099  - http://mdc.sagepub.com/content/14/43/10.short
4100  - http://mdc.sagepub.com/content/14/43/10.full
AB  - This article describes the 2-year outcomes of the Intravitreal Alfibercept Injection in Vision Impairment Due to DME [VIVID; NCT01331681] trial as well as the Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema [VISTA; NCT01363440]. VIVID and VISTA are both phase III, randomized, double-blind global studies in which intravitreal aflibercept was injected to treat diabetic macular edema.